Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy?

Immunic, Inc. (NASDAQ:IMUX)’s stock price rose 9.3% during mid-day trading on Monday . The company traded as high as $0.6529 and last traded at $0.6372. Approximately 1,596,354 shares were traded during trading, an increase of 14% from the average daily volume of 1,401,934 shares. The stock had previously closed at $0.5830.

Analyst Ratings Changes

IMUX has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. HC Wainwright lowered their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Roth Capital began coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price objective for the company. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Finally, D. Boral Capital cut their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $7.40.

Immunic Price Performance

The firm has a market capitalization of $76.65 million, a PE ratio of -0.77 and a beta of 1.54. The business’s 50 day moving average is $0.67 and its two-hundred day moving average is $0.79.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Analysts expect that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the company. Focus Partners Wealth lifted its position in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after buying an additional 415,104 shares during the last quarter. Aberdeen Group plc grew its position in Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after acquiring an additional 7,184,457 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Immunic during the third quarter worth approximately $29,000. Millennium Management LLC lifted its holdings in shares of Immunic by 414.5% in the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after acquiring an additional 427,361 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Immunic in the 3rd quarter valued at $170,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.